Literature DB >> 14658990

Establishment of remission criteria for anxiety disorders.

Alicia C Doyle1, Mark H Pollack.   

Abstract

Anxiety disorders such as generalized anxiety disorder, social anxiety disorder, panic disorder, and posttraumatic stress disorder are typically chronic conditions associated with high health care costs and are often accompanied by psychiatric comorbidity, including major depressive disorder, substance abuse, and other anxiety disorders. Anxiety disorders are associated with significant functional impairment in social, vocational, and familial spheres and with diminished overall quality of life. The following clinical overview provides informal guidelines for identifying remission in patients with an anxiety disorder. A systematic approach to treatment that includes patient education, encouragement of exposure, attention to relevant comorbidities, use of empirically proven pharmacotherapies, and psychosocial interventions of adequate intensity and duration will improve outcomes and move patients toward marked improvement and remission.

Entities:  

Mesh:

Year:  2003        PMID: 14658990

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  On the concept of remission in schizophrenia.

Authors:  Stefan Leucht; Romain Beitinger; Werner Kissling
Journal:  Psychopharmacology (Berl)       Date:  2007-07-06       Impact factor: 4.530

2.  Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Authors:  Michael Rufer; Iver Hand; Heike Alsleben; Anne Braatz; Jürgen Ortmann; Birgit Katenkamp; Susanne Fricke; Helmut Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

3.  Managing schizophrenia in primary care: the utility of remission criteria as outcome indicators.

Authors:  Christopher Fear; David Yeomans; Bryan Moore; Mark Taylor; Keith Ford; Alan Currie; Joanne Hynes; Gary Sullivan; Richard Whale; Tom Burns
Journal:  Ment Health Fam Med       Date:  2009-06

Review 4.  Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder.

Authors:  J Antoni Ramos-Quiroga; Miguel Casas
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

5.  Effectiveness of therapeutic massage for generalized anxiety disorder: a randomized controlled trial.

Authors:  Karen J Sherman; Evette J Ludman; Andrea J Cook; Rene J Hawkes; Peter P Roy-Byrne; Susan Bentley; Marissa Z Brooks; Daniel C Cherkin
Journal:  Depress Anxiety       Date:  2010-05       Impact factor: 6.505

6.  Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.

Authors:  Murray B Stein; Mark H Pollack; Alexander Bystritsky; Jeffrey E Kelsey; Richard M Mangano
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

8.  Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians.

Authors:  Hannu Koponen; Christer Allgulander; Janelle Erickson; Eduardo Dunayevich; Yili Pritchett; Michael J Detke; Susan G Ball; James M Russell
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

9.  Pharmacological management of panic disorder.

Authors:  Carlo Marchesi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

10.  Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Karla J Alaka; William Noble; Angel Montejo; Héctor Dueñas; Autar Munshi; Jeffrey R Strawn; Alan Lenox-Smith; Jonna Ahl; Leszek Bidzan; Brita Dorn; Susan Ball
Journal:  Int J Geriatr Psychiatry       Date:  2014-02-20       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.